Table 3 Univariate and multivariate analysis between virological Failure and adequate virological response
From: Outcome of patients on second line antiretroviral therapy under programmatic condition in India
Characteristics | Uni-variate | p-value | Multi-variate | p-value |
|---|---|---|---|---|
Odds ratio (95 % CI) | Odds ratio (95 % CI) | |||
Age (years) | ||||
>40 | 1.249 (0.496-3.147) | 0.637 | ||
≤40 | 1 | |||
Sex | ||||
Male | 0.423 (0.161-1.112) | 0.081 | ||
Female | 1 | |||
WHO Stage 1st line | ||||
III + IV | 1.038 (0.400-2.698) | 0.938 | ||
I + II | 1 | |||
Tuberculosis 1st line | ||||
Yes | 2.327 (0.968-2.327) | 0.059 | ||
No | 1 | |||
Adherence 1st line | ||||
<95 % | 2.600 (1.090-6.201) | 0.031 | 1.918 (0.741-4.962) | 0.180 |
>95 % | 1 | 1 | ||
Weight (Kg) 1st line | ||||
≤45 | 1.215 (0.517-2.854) | 0.655 | ||
>45 | 1 | |||
CD4 count 1st line (/μL) | ||||
<200 | 3.618 (1.455-8.998) | 0.006 | 2.788 (1.045-7.439) | 0.041 |
>200 | 1 | 1 | ||
Duration of Immunological failure (months) | ||||
>12 | 0.542 (0.229-1.283) | 0.164 | ||
<12 | 1 | |||
Clinical failure | ||||
Yes | 5.253 (0.673-40.976) | 0.114 | ||
No | 1 | |||
CD4 count less than baseline | ||||
Yes | 2.335 (0.949-5.749) | 0.065 | ||
No | 1 | |||
50 % fall from peak CD4 count | ||||
Yes | 1.092 (0.339-3.519) | 0.882 | ||
No | 1 | |||
CD4 count < 100/μL | ||||
Yes | 0.688 (0.297-1.593) | 0.382 | ||
No | 1 | |||
CD4 count 2nd line (/μL) | ||||
<200 | 3.275 (0.856-12.537) | 0.083 | ||
>200 | 1 | |||
WHO Stage 2nd line | ||||
III + IV | 1.287 (0.477-3.477) | 0.618 | ||
I + II | 1 | |||
Weight (Kg) 2nd line | ||||
≤45 | 1.143 (0.492-2.653) | 0.756 | ||
>45 | 1 | |||
Viral Load 2nd Line (copies/ml) | ||||
>177000 | 3.558 (1.399-9.050) | 0.008 | 3.402 (1.272-9.097) | 0.015 |
≤177000 | 1 | 1 | ||
Tuberculosis 2nd line | ||||
Yes | 1.364 (0.455-4.090) | 0.580 | ||
No | 1 | |||
Adherence 2nd line | ||||
<95 % | 2.870 (1.176-7.004) | 0.021 | 2.788 (1.044-7.445) | 0.041 |
>95 % | 1 | 1 | ||